Together we shape the future of oncologic surgery
Cebiotex is a Phase 2 clinical-stage biotechnology company developing
innovative local therapies for oncology. Using proprietary nanofiber engineering,
we enable controlled release of anti-tumor agents directly at the surgical site,
aiming to optimize outcomes and reduce recurrence.
Our technology bridges science and surgery to bring safer and more effective
treatments to patients.
Technology platform
At Cebiotex, we advance surgical outcomes by leveraging our proprietary nanofiber engineering technology platform to eliminate residual cancer cells following tumor resection.
CEB-01
The lead clinical candidate CEB-01 is a membrane loaded with SN-38 placed directly at the tumor resection site, delivering a sustained release of SN-38 and enhancing
postoperative tumor control.
Latest news
Cebiotex appoints Joan Torrejon as its new CEO
Cebiotex begins a new stage with a change in its executive management...
Cebiotex obtains EMA ODD for CEB-01 in Pancreatic Cancer
Cebiotex is proud to announce that CEB-01, our lead product for local...
CEBIOTEX receives approval to initiate a paediatric phase II clinical trial for locally resectable abdominal tumours
We are excited to share that the clinical trial to evaluate the...
Our partners
